Novoprotein Scientific Inc. (SHA:688137)
China · Delayed Price · Currency is CNY 72.49
+3.72 (5.41%)
Sep 1, 2026, 4:00 PM EDT
Novoprotein Scientific Revenue
Novoprotein Scientific had revenue of 41.25M CNY in the quarter ending June 30, 2026, with 6.73% growth. This brings the company's revenue in the last twelve months to 152.84M, up 9.18% year-over-year. In the year 2025, Novoprotein Scientific had annual revenue of 146.44M with 14.80% growth.
Revenue (ttm)
152.84M
Revenue Growth
+9.18%
P/S Ratio
33.14
Revenue / Employee
240.32K
Employees
636
Market Cap
5.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.44M | 18.88M | 14.80% |
| Dec 31, 2024 | 127.56M | -25.64M | -16.73% |
| Dec 31, 2023 | 153.19M | -111.36M | -42.09% |
| Dec 31, 2022 | 264.55M | -77.34M | -22.62% |
| Dec 31, 2021 | 341.90M | 162.05M | 90.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Hvsen Biotechnology | 1.72B |
| Shenzhen Weiguang Biological Products | 1.20B |
| ChemPartner PharmaTech | 1.14B |
| Boji Medical Technology | 961.34M |
| R&G PharmaStudies | 939.31M |
| Beijing Konruns Pharmaceutical | 917.05M |
| Wuhan Keqian Biology Co.,Ltd | 836.28M |
| PharmaResources (Shanghai) | 700.02M |